BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Collaboration with JelikaLite

March 17, 2021 08:33:33

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, recently announced a collaboration with JelikaLite, a company developing Cognilum(TM), a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial. In the trial, “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children,” brain treatments for children diagnosed with autism would be delivered through Cognilum, while Brain Scientific’s NeuroEEG, a wireless EEG device, will monitor brain activity. The trial is designed to provide researchers and clinicians an opportunity to potentially uncover new treatment options for reducing the symptoms children with autism experience. “We are delighted to begin this collaboration with JelikaLite,” said Brain Scientific’s Director of Marketing, Irina Nazarova. “Our Neuro EEG solutions have a wide range of applications and helping to monitor children with autism to improve their well-being would be an important step towards a wider adoption of affordable and accessible EEG systems like ours.”

To view the full press release, visit

About Brain Scientific

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork